Corpusense

Boston Scientific (BSX) earnings call transcript summary & sentiment

Last call Wed 29 Jul 2026·Next Wed 28 Oct 2026

Our read on the 29 July 2026 earnings call

Overall tone: Negative due to sharp guidance reductions in core growth drivers Watchman and Electrophysiology (EP)

Overall tone

Negative due to sharp guidance reductions in core growth drivers Watchman and Electrophysiology (EP)

Executive Summary

Boston Scientific delivered solid Q2 2026 results with 7% organic revenue growth and 15% adjusted EPS growth to $0.86, beating expectations due to favorable discrete tax items.

Core Signals

Revenue Growth & Demand: Organic revenue grew 7.0% in Q2 2026, but full-year 2026 organic growth guidance was lowered to 5%-6% (with Q3 guided to 3%-5%) due to an unexpected slowdown in Watchman and US EP share loss.

Bullish Signals

Interventional Cardiology and Vascular Therapies delivered 12% operational growth in Q2 driven by 15% growth in interventional cardiology with strength across complex PCI, imaging, and drug-coated balloons.

Risk Signals

Full-year 2026 organic revenue guidance was cut to 5%-6%, with Q3 organic growth slowing to 3%-5%.

Q&A Signals

Repeated analyst topics: Analysts repeatedly questioned Watchman referral slowdown causes, 2027 revenue and EPS growth expectations, and US EP competitive share loss dynamics.

Key Investor Debate

The key investor debate centers on whether the structural growth story for Watchman and EP is permanently impaired or merely experiencing a temporary operational transition.

Analyst Takeaway

Management's transparent resetting of expectations creates a challenging near-term setup for 2H 2026 and FY2027, as previous hyper-growth drivers turn into growth drags.

Those are the opening lines. The full read covers the whole earnings transcript: every bullish and bearish signal, what analysts pressed hardest on, and where management answered vaguely — each with the quote behind it. Every line sourced.

See the full Earnings Highlight

Themes across Boston Scientific and the Health Care sector

Analyse a theme over quarters — what's brand new, what's being talked about more, and what is spreading to more companies across the sector.

Unlock themes

Ask about Boston Scientific's earnings, or other S&P 500 earnings calls

Ask across the corpus, instead of reading one call at a time. Scope it to Boston Scientific, its sector, or every name we cover — plain English, no operators — and answers come back structured: a summary, the drivers, and a read on each company.

"What did Boston Scientific say about margins, and did the framing change from last quarter?"

"Did Boston Scientific's management walk back any full-year guidance, and how did they frame it?"

"Where did Boston Scientific avoid answering on capital allocation?"

Unlock search

Earnings call history & sentiment

All 7 of its last calls fell on a Wednesday.

Date Day Period Corpusense read
2026-07-29Wednesday2026 Q3Negative due to sharp guidance reductions in core growth drivers Watchman and Electrophysiology (EP)
2026-04-22Wednesday2026 Q2Negative
2026-02-04Wednesday2026 Q1Positive
2025-10-22Wednesday2025 Q4—
2025-07-23Wednesday2025 Q3—
2025-04-23Wednesday2025 Q2—
2025-02-05Wednesday2025 Q1—

Earnings calls across Health Care Equipment & Supplies

The companies Boston Scientific is read alongside. Each has its own earnings call dates and sentiment.

ABTAbbott LaboratoriesALGNAlign TechnologyBAXBaxter InternationalBDXBecton DickinsonCOOCooper Companies (The)DXCMDexcomEWEdwards LifesciencesGEHCGE HealthCare

Boston Scientific is one of the S&P 500 companies we track

Sentiment analysis on any single earnings call, themes building across a sector, and search across every company and quarter — each claim linked back to the passage it came from.

Create a free account See the full calendar Plans & pricing